Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | EED | O75530 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555998 | 0.86 | CCNC (0.37) | FPR1FPR2CCNCCDK8EED | |
| SCHEMBL3550705 | 0.80 | RORC (0.33) | RORC | |
| SCHEMBL27258755 | 0.71 | DRD2 (0.59) | RORCDRD2DRD3MTNR1AMTNR1B | |
| SCHEMBL3551801 | 0.70 | CASP6 (0.50) | FPR1FPR2DRD2DRD3CCNC | |
| SCHEMBL20887685 | 0.70 | ME3 (0.52) | FPR1FPR2DRD2DRD3CCNC | |
| SCHEMBL3551660 | 0.70 | CASP6 (0.50) | FPR1FPR2DRD2DRD3CCNC | |
| SCHEMBL5203906 | 0.70 | CASP6 (0.50) | FPR1FPR2DRD2DRD3CCNC | |
| SCHEMBL3561589 | 0.69 | MCHR1 (0.47) | FPR1FPR2DRD2DRD3CCNC | |
| Hydrochloric Acid SCHEMBL5406630 | 0.69 | FPR1 (0.49) | FPR1FPR2DRD2DRD3CCNC | |
| Hydrochloric Acid SCHEMBL5383077 | 0.69 | FPR1 (0.49) | FPR1FPR2DRD2DRD3CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | FPR1 3252/4885FPR2 4303/4885RORC 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.